1-甲基哌啶-4-酮 肟 | 1515-27-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-甲基哌啶-4-酮 肟
• 中文别名: N-甲基-4-哌啶酮肟；1-甲基哌啶-4-酮肟
• 英文名称: 1-methylpiperidin-4-one oxime
• 英文别名: N-(1-methylpiperidin-4-ylidene)hydroxylamine
• CAS: 1515-27-1
• 化学式: C₆H₁₂N₂O
• mdl: MFCD00173927
• 分子量: 128.174
• InChiKey: PMWKIHOURGCZOJ-UHFFFAOYSA-N

物化性质

• 熔点：
  128.5-129℃
• 沸点：
  220.9±33.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  35.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-甲基哌啶-4-酮 肟 在 sodium hydroxide 、 苯磺酰氯 作用下， 以 丙酮 为溶剂， 反应 18.0h， 生成 1-甲基-1,4-二氮杂庚烷-5-酮
  参考文献：
  名称：

  Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase

  摘要：

  The potency and selectivity of a series of 5-hetero-2-iminohexahydroazepines were examined as inhibitors or the three human NOS isoforms. The effect or ring substitution of the 5-carbon for a heteroatom is presented. Potencies (IC50's) for these inhibitors are in the low micromolar range for hi-NOS with some examples exhibiting a 500x selectivity versus hec-NOS. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00523-6
• 作为产物：
  描述：

  1-甲基-4-哌啶酮-3-羧酸甲酯 在 盐酸 、 水 作用下， 生成 1-甲基哌啶-4-酮 肟
  参考文献：
  名称：

  Tomita, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1951, vol. 71, p. 1053,1057

  摘要：

  DOI：

文献信息

• Npy antagonists, preparation and uses
  申请人：Botez Iuliana

  公开号：US20090233910A1

  公开（公告）日：2009-09-17

  The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.

  本发明涉及新颖化合物，它们的制备和用途，特别是在治疗方面的用途。更具体地说，它涉及至少具有两个芳香环的衍生化合物，它们的制备和用途，特别是在人类或动物健康领域。这些化合物对存在于中枢和外周神经系统中的神经肽Y（NPY）的生物受体具有亲和力。本发明的化合物优选为NPY拮抗剂，更具体地说是NPY Y1亚型的拮抗剂，因此可用于治疗或预防涉及NPY的任何疾病。本发明还涉及含有所述化合物的药物组合物，其制备和用途，以及使用所述化合物的治疗方法。
• [EN] CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT<br/>[FR] DÉRIVÉ DE CYCLOHEXÈNE, SON PROCÉDÉ DE PRÉPARATION ET COMPOSITION PHARMACEUTIQUE POUR PRÉVENIR OU TRAITER UNE MALADIE MÉTABOLIQUE, CONTENANT LEDIT DÉRIVÉ COMME PRINCIPE ACTIF
  申请人：HYUNDAI PHARM CO LTD

  公开号：WO2017078352A1

  公开（公告）日：2017-05-11

  The present invention relates to: a cyclohexene derivative; a preparation method thereof; and a pharmaceutical composition for preventing or treating metabolic disease comprising the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (cAMP) by activating G protein-coupled receptor 119 (GPR-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (GLP-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome X.

  本发明涉及：一种环己烯衍生物；其制备方法；以及一种包含该衍生物作为活性成分的用于预防或治疗代谢疾病的药物组合物。根据本发明的环己烯衍生物通过激活G蛋白偶联受体119（GPR-119）增加了细胞内环状腺苷一磷酸（cAMP）的活性，并通过诱导释放神经内分泌蛋白胰高血糖素样肽-1（GLP-1），同时表现出减肥和降糖效果，因此可作为预防或治疗诸如肥胖、1型糖尿病、2型糖尿病、葡萄糖耐量不足、胰岛素抵抗、高血糖、高脂血症、高甘油三酯血症、高胆固醇血症、血脂异常和综合征X等代谢疾病的药物组合物。
• NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF
  申请人：Frost Lisa M.

  公开号：US20090281062A1

  公开（公告）日：2009-11-12

  The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.

  本发明涉及亚硝基衍生物，包括在生理条件下捐赠亚硝基（HNO）的羟基亚硝基化合物的羧酸和磷酸酯。发明中的化合物和组合物可用于治疗和/或预防对亚硝基疗法有响应的疾病或病症的发作和/或发展，包括心力衰竭、缺血/再灌注损伤和癌症。
• BENZOFURO[3,2-c] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA
  申请人：GUZZO Peter R.

  公开号：US20120184531A1

  公开（公告）日：2012-07-19

  The present invention relates to benzofuro[3,2-c]pyridine and azepine analogs as serotonin sub-type 6 (5-HT 6 ) modulators, pharmaceutical compositions including these compounds, methods of preparation, and use thereof. These compounds are useful in the treatment of central nervous system disorders including obesity, metabolic syndrome, cognition, schizophrenia, attention deficit hyperactivity disorder, bipolar disorder, rare and orphan diseases, and sleep disorders. The subject compounds have the structure of formula (I) with the substituents being described herein.

  本发明涉及苯并呋喃[3,2-c]吡啶和氮杂环庚烯类似物作为5-羟色胺亚型6（5-HT6）调节剂，包括这些化合物的药物组合物，其制备方法以及使用方法。这些化合物在治疗包括肥胖、代谢综合征、认知障碍、精神分裂症、注意力缺陷多动障碍、躁郁症、罕见和孤儿疾病以及睡眠障碍在内的中枢神经系统疾病中是有用的。所述化合物具有如下式（I）的结构，其中所述取代基在此处描述。
• X=Y-ZH systems as potential 1,3-dipoles. Part 34. generation of nitrones from oximes. Tandem michael addition-1,3-dipolar cycloaddition reactions. class 2 processes utilising bifunctional michael acceptor-dipolarophile components.
  作者：Ronald Grigg、Michael J. Dorrity、Frances Heaney、John F. Malone、Shuleewan Rajviroongit、Visuvanathar Sridharan、Sivagnanasundram Surendrakumar

  DOI：10.1016/s0040-4020(01)91022-1

  日期：1991.9

  Aldoximes and ketoximes react with a range of bifunctional Michael acceptor-dipolarophile substrates comprising functionalised 1,3-, 1,4- and 1,5-dienes via a tandem process involving an N-alkenyl nitrone intermediate. The 1,3-dienes react regio- and stereo-specifically to give 1-aza-7-oxabicyclo[2.2.1]heptanes whilst sterically unencumbered aryl aldoximes and 1,4-dienes give 1-aza-2-oxabicyclo[3.2

  醛酮肟和酮肟通过涉及N-烯基硝酮中间体的串联过程与一系列包含官能化的1,3-，1,4-和1,5-二烯的双官能Michael受体-双极性亲和底物反应。1,3-二烯在区域和立体上发生特异性反应，生成1-氮杂-7-氧杂双环[2.2.1]庚烷，而空间上不受阻碍的芳基醛肟和1,4-二烯生成1-氮杂-2-氧杂双环[3.2]。 1]辛烷衍生物。1-Aza-2-oxa-和1-aza-8-oxa-双环[3.2.1]辛烷的酮肟和1.4消旋混合物。1,5-二烯和酮肟与区域和立体特异性反应，生成1-aza-8-氧杂双环[3.2.1]辛烷衍生物，而苯甲醛肟则生成1：1异构体的1-aza-8-氧杂双环[3.2]混合物。 1]辛烷以及两个差向异构的1-氮杂-2-氧杂双环[3.2.1]辛烷。串联过程的区域和立体化学结果受双功能底物中连接链的长度和性质以及在过渡状态下肟和双极性亲核体上取代基之间的空间相互作用所控制。据报道1-氮杂-7-氧杂双环[2